Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

Table of Contents

February 1, 2022; Volume 63,Issue 2

This Month in JNM

  • You have access
    This Month in JNM
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 10A;

Discussions with Leaders

  • You have access
    A European Oncology Leader Looks at PSMA
    Silke Gillessen, Johannes Czernin and Ken Herrmann
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 169-171; DOI: https://doi.org/10.2967/jnumed.121.263729

The State of The Art

  • You have access
    A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies
    Fanny Orlhac, Jakoba J. Eertink, Anne-Ségolène Cottereau, Josée M. Zijlstra, Catherine Thieblemont, Michel Meignan, Ronald Boellaard and Irène Buvat
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 172-179; DOI: https://doi.org/10.2967/jnumed.121.262464

Hot Topics

  • You have access
    Is It Too Soon to Know When It’s LATE?
    Angela C. Rieger and Daniel H.S. Silverman
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 180-182; DOI: https://doi.org/10.2967/jnumed.121.263229

Focus on Molecular Imaging

  • Visualizing T-Cell Responses: The T-Cell PET Imaging Toolbox
    You have access
    Visualizing T-Cell Responses: The T-Cell PET Imaging Toolbox
    Chao Li, Chaozhe Han, Shao Duan, Ping Li, Israt S. Alam and Zunyu Xiao
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 183-188; DOI: https://doi.org/10.2967/jnumed.121.261976

Standard Of Care

  • You have access
    Management of Differentiated Thyroid Cancer: The Standard of Care
    Anca M. Avram, Katherine Zukotynski, Helen Ruth Nadel and Luca Giovanella
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 189-195; DOI: https://doi.org/10.2967/jnumed.121.262402

Editorial

  • You have access
    Managing a High-Specific-Activity Iobenguane Therapy Clinic: From Operations to Reimbursement
    Sophia R. O’Brien and Daniel A. Pryma
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 196-198; DOI: https://doi.org/10.2967/jnumed.121.262306

Oncology

  • Clinical

    • 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
      You have access
      18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma
      Matthias R. Benz, Wesley R. Armstrong, Francesco Ceci, Giulia Polverari, Timothy R. Donahue, Zev A. Wainberg, Andrew Quon, Martin Auerbach, Mark D. Girgis, Ken Herrmann, Johannes Czernin and Jeremie Calais
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 199-204; DOI: https://doi.org/10.2967/jnumed.121.261952
    • <sup>131</sup>I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors
      You have access
      131I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors
      Ying Zhang, Juergen Kupferschlaeger, Peter Lang, Gerald Reischl, Rupert J. Handgretinger, Christian la Fougère and Helmut Dittmann
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 205-211; DOI: https://doi.org/10.2967/jnumed.120.261854

Theranostics

  • Clinical

    • Detecting Fibroblast Activation Proteins in Lymphoma Using <sup>68</sup>Ga-FAPI PET/CT
      You have access
      Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT
      Xiao Jin, Maomao Wei, Shuailiang Wang, Guochang Wang, Yumei Lai, Yunfei Shi, Yan Zhang, Zhi Yang and Xuejuan Wang
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 212-217; DOI: https://doi.org/10.2967/jnumed.121.262134
    • Efficacy and Safety of <sup>177</sup>Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
      You have access
      Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
      Lamiaa Zidan, Amir Iravani, Kira Oleinikov, Simona Ben-Haim, David J. Gross, Amichay Meirovitz, Ophra Maimon, Tim Akhurst, Michael Michael, Rodney J. Hicks, Simona Grozinsky-Glasberg and Grace Kong
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 218-225; DOI: https://doi.org/10.2967/jnumed.120.260760
    • Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?
      You have access
      Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?
      Andrei Gafita, Hui Wang, Andrew Robertson, Wesley R. Armstrong, Raphael Zaum, Manuel Weber, Farid Yagubbayli, Clemens Kratochwil, Tristan R. Grogan, Kathleen Nguyen, Fernando Navarro, Rouzbeh Esfandiari, Isabel Rauscher, Bjoern Menze, David Elashoff, Ebrahim S. Delpassand, Ken Herrmann, Johannes Czernin, Michael S. Hofman, Jeremie Calais, Wolfgang P. Fendler and Matthias Eiber
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 226-232; DOI: https://doi.org/10.2967/jnumed.121.261906
    • aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in <sup>18</sup>F-DCFPyL Images of Veterans with Prostate Cancer
      You have access
      aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in 18F-DCFPyL Images of Veterans with Prostate Cancer
      Nicholas Nickols, Aseem Anand, Kerstin Johnsson, Johan Brynolfsson, Pablo Borreli, Neil Parikh, Jesus Juarez, Lida Jafari, Mattias Eiber and Matthew Rettig
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 233-239; DOI: https://doi.org/10.2967/jnumed.120.261863
    • Diagnostic Performance and Clinical Impact of <sup>68</sup>Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)
      Open Access
      Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)
      Juliano J. Cerci, Stefano Fanti, Enrique E. Lobato, Jolanta Kunikowska, Omar Alonso, Sevastian Medina, Fuad Novruzov, Thabo Lengana, Carlos Granados, Rakesh Kumar, Venkatesh Rangarajan, Akram Al-Ibraheem, Mukbil Hourani, Nor S. Ali, Azra Ahmad, Zohar Keidar, Ozlem Küçük, Umut Elboga, Mateos Bogoni and Diana Paez
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 240-247; DOI: https://doi.org/10.2967/jnumed.120.261886
    • BRIEF COMMUNICATION

      • The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
        You have access
        The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
        Liang Dong, Yun Su, Yinjie Zhu, Mark C. Markowski, Mei Xin, Michael A. Gorin, Baijun Dong, Jiahua Pan, Martin G. Pomper, Jianjun Liu, Kenneth J. Pienta, Wei Xue and Steven P. Rowe
        Journal of Nuclear Medicine February 1, 2022, 63 (2) 248-252; DOI: https://doi.org/10.2967/jnumed.121.262411
    • Kidney Doses in <sup>177</sup>Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
      You have access
      Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
      Michael Mix, Tobias Renaud, Felix Kind, Ursula Nemer, Elham Yousetzadeh-Nowsha, Tumelo C.G. Moalosi, Aymen M. Ormrane, Philipp T. Meyer and Juri Ruf
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 253-258; DOI: https://doi.org/10.2967/jnumed.121.262245
  • Basic

    • FEATURED BASIC SCIENCE ARTICLE

      • An Improved <sup>211</sup>At-Labeled Agent for PSMA-Targeted α-Therapy
        You have access
        An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy
        Ronnie C. Mease, Choong Mo Kang, Vivek Kumar, Sangeeta Ray Banerjee, Il Minn, Mary Brummet, Kathleen L. Gabrielson, Yutian Feng, Andrew Park, Ana P. Kiess, George Sgouros, Ganesan Vaidyanathan, Michael R. Zalutsky and Martin G. Pomper
        Journal of Nuclear Medicine February 1, 2022, 63 (2) 259-267; DOI: https://doi.org/10.2967/jnumed.121.262098

Infectious Disease

  • Clinical

    • INVITED PERSPECTIVE

      • You have access
        Imaging in Post-COVID Lung Disease: Does 18F-FDG PET/CT Have the Key?
        Olivier Gheysens, Leïla Belkhir and François Jamar
        Journal of Nuclear Medicine February 1, 2022, 63 (2) 268-269; DOI: https://doi.org/10.2967/jnumed.121.263166
    • BRIEF COMMUNICATION

      • Evolution of <sup>18</sup>F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation
        Open Access
        Evolution of 18F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation
        Andrew Thornton, Francesco Fraioli, Simon Wan, Helen S. Garthwaite, Balaji Ganeshan, Robert I. Shortman, Raymond Endozo, Stefan Vöö, Irfan Kayani, Deena Neriman, Leon Menezes, Jamshed Bomanji, Toby Hilllman, Melissa Heightman, Joanna C. Porter and Ashley M. Groves
        Journal of Nuclear Medicine February 1, 2022, 63 (2) 270-273; DOI: https://doi.org/10.2967/jnumed.121.262296
    • Incidental Findings Suggestive of COVID-19 Pneumonia in Oncologic Patients Undergoing <sup>18</sup>F-FDG PET/CT Studies: Association Between Metabolic and Structural Lung Changes
      Open Access
      Incidental Findings Suggestive of COVID-19 Pneumonia in Oncologic Patients Undergoing 18F-FDG PET/CT Studies: Association Between Metabolic and Structural Lung Changes
      Cristina Gamila Wakfie-Corieh, Federico Ferrando-Castagnetto, Alba María Blanes García, Marta García García-Esquinas, Aída Ortega Candil, Cristina Rodríguez Rey, María Nieves Cabrera-Martín, Ana Delgado Cano and José Luis Carreras Delgado
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 274-279; DOI: https://doi.org/10.2967/jnumed.121.261915

Cardiovascular

  • Clinical

    • Comparing Semiquantitative and Qualitative Methods of Vascular <sup>18</sup>F-FDG PET Activity Measurement in Large-Vessel Vasculitis
      You have access
      Comparing Semiquantitative and Qualitative Methods of Vascular 18F-FDG PET Activity Measurement in Large-Vessel Vasculitis
      Himanshu R. Dashora, Joel S. Rosenblum, Kaitlin A. Quinn, Hugh Alessi, Elaine Novakovich, Babak Saboury, Mark A. Ahlman and Peter C. Grayson
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 280-286; DOI: https://doi.org/10.2967/jnumed.121.262326

Neurology

  • Clinical

    • Dynamic Amyloid PET: Relationships to <sup>18</sup>F-Flortaucipir Tau PET Measures
      You have access
      Dynamic Amyloid PET: Relationships to 18F-Flortaucipir Tau PET Measures
      Fabio Raman, Yu-Hua Dean Fang, Sameera Grandhi, Charles F. Murchison, Richard E. Kennedy, John C. Morris, Parinaz Massoumzadeh, Tammie Benzinger, Erik D. Roberson and Jonathan McConathy
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 287-293; DOI: https://doi.org/10.2967/jnumed.120.254490
  • Basic

    • Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots
      You have access
      Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots
      Javad Khodaii, Mostafa Araj-Khodaei, Manouchehr S. Vafaee, Dean F. Wong and Albert Gjedde
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 294-301; DOI: https://doi.org/10.2967/jnumed.117.204453
    • <sup>11</sup>C-PiB and <sup>124</sup>I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention
      Open Access
      11C-PiB and 124I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention
      Silvio R. Meier, Dag Sehlin, Sahar Roshanbin, Victoria Lim Falk, Takashi Saito, Takaomi C. Saido, Ulf Neumann, Johanna Rokka, Jonas Eriksson and Stina Syvänen
      Journal of Nuclear Medicine February 1, 2022, 63 (2) 302-309; DOI: https://doi.org/10.2967/jnumed.121.262083

Endocrinology

  • Clinical

    • FEATURED ARTICLE OF THE MONTH

      • <sup>68</sup>Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism
        Open Access
        68Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism
        Marti Boss, Christof Rottenburger, Winfried Brenner, Oliver Blankenstein, Vikas Prasad, Sonal Prasad, Paolo de Coppi, Peter Kühnen, Mijke Buitinga, Pirjo Nuutila, Timo Otonkoski, Khalid Hussain, Maarten Brom, Annemarie Eek, Jamshed Bomanji, Pratik Shah and Martin Gotthardt
        Journal of Nuclear Medicine February 1, 2022, 63 (2) 310-315; DOI: https://doi.org/10.2967/jnumed.121.262327

Special Contribution

  • You have access
    RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals, Part 1—Collection of Data for Radiopharmaceutical Dosimetry
    Michael G. Stabin, Richard E. Wendt and Glenn D. Flux
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 316-322; DOI: https://doi.org/10.2967/jnumed.120.259200

Letters To The Editor

  • You have access
    Commercially Competitive Vendor-Agnostic Image Reconstruction Could Be a Leap Forward for PET Harmonization
    Adam L Kesner
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 323-324; DOI: https://doi.org/10.2967/jnumed.121.263421
  • You have access
    A VISION of ALSYMPCA
    Paulo Schiavom Duarte
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 324; DOI: https://doi.org/10.2967/jnumed.121.263160
  • You have access
    Reply: A VISION of ALSYMPCA
    Oliver Sartor
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 324-325; DOI: https://doi.org/10.2967/jnumed.121.263193
  • You have access
    On Semiquantitative Methods for Assessing Vascular 18F-FDG PET Activity in Large-Vessel Vasculitis
    Eric Laffon and Roger Marthan
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 325-326; DOI: https://doi.org/10.2967/jnumed.121.263060
  • You have access
    Reply: On Semiquantitative Methods for Assessing Vascular 18F-FDG PET Activity in Large-Vessel Vasculitis
    Mark A. Ahlman, Roberto Maass-Moreno and Peter C. Grayson
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 326; DOI: https://doi.org/10.2967/jnumed.121.263158

Erratum

  • You have access
    Erratum
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 252;

SNMMI Newsline

  • You have access
    SNMMI Newsline
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 23N-34N;
  • You have access
    Joint NIBIB/NCI/SNMMI Workshop on Directly Imaging Targeted Radionuclide Therapy Isotopes
    I. George Zubal and Jacek Capala
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 23N-25N;
  • You have access
    DOE and HHS Certify Sufficient 99Mo Supplies
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 26N;
  • You have access
    FDA Approves New 68Ga Kit for Prostate Cancer PET
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 26N;
  • You have access
    SNMMI to Host Summits on Artificial Intelligence and Patient Access
    Richard L. Wahl
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 27N;
  • You have access
    Newsbriefs
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 28N-29N;
  • You have access
    From the Literature
    Journal of Nuclear Medicine February 1, 2022, 63 (2) 30N-34N;
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 63 (2)
Journal of Nuclear Medicine
Vol. 63, Issue 2
February 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)

Issue highlights

  • 68Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism
  • An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy
Sign up for alerts

Jump to

  • This Month in JNM
  • Discussions with Leaders
  • The State of The Art
  • Hot Topics
  • Focus on Molecular Imaging
  • Standard Of Care
  • Editorial
  • Oncology
    • Clinical
  • Theranostics
    • Clinical
      • BRIEF COMMUNICATION
    • Basic
      • FEATURED BASIC SCIENCE ARTICLE
  • Infectious Disease
    • Clinical
      • INVITED PERSPECTIVE
      • BRIEF COMMUNICATION
  • Cardiovascular
    • Clinical
  • Neurology
    • Clinical
    • Basic
  • Endocrinology
    • Clinical
      • FEATURED ARTICLE OF THE MONTH
  • Special Contribution
  • Letters To The Editor
  • Erratum
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
  • First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer
  • Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
  • Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study
  • Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors
More...
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire